Search results
Results From The WOW.Com Content Network
The main types of RNA therapeutics are those based on messenger RNA (mRNA), antisense RNA (asRNA), RNA interference (RNAi), and RNA aptamers. Of the four types, mRNA-based therapy is the only type which is based on triggering synthesis of proteins within cells, making it particularly useful in vaccine development. [ 3 ]
CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and ...
Pharmacological Reviews is a quarterly peer-reviewed scientific journal publishing review articles on all aspects of pharmacology and related topics. It is published by the American Society for Pharmacology and Experimental Therapeutics. The editor-in-chief is Lynette C. Daws (The University of Texas Health Science Center at San Antonio).
The society publishes three research journals and a review journal: the Journal of Pharmacology and Experimental Therapeutics, Drug Metabolism and Disposition, Molecular Pharmacology, and Pharmacological Reviews. Starting in 2012 these publications are only offered online.
On Wednesday, AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based ...
The superstar and some of her closest loved ones discuss her life and loves in the new documentary 'Liza: A Truly Terrific Absolutely True Story'
The 2025 Grammy Awards are here, people! And this year, the list of A-list attendees is fully stacked, meaning the red carpet is obviously full of head-turning looks. While the night's most highly ...
ProQR Therapeutics NV (NASDAQ: PRQR) is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. [1] The company was funded in 2012 by chief executive officer (CEO) Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called ...